CA2104899C - Antibodies to plasmodium falciparum - Google Patents
Antibodies to plasmodium falciparum Download PDFInfo
- Publication number
- CA2104899C CA2104899C CA002104899A CA2104899A CA2104899C CA 2104899 C CA2104899 C CA 2104899C CA 002104899 A CA002104899 A CA 002104899A CA 2104899 A CA2104899 A CA 2104899A CA 2104899 C CA2104899 C CA 2104899C
- Authority
- CA
- Canada
- Prior art keywords
- hrp
- antibody
- peptide
- plasmodium falciparum
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000223960 Plasmodium falciparum Species 0.000 title claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 83
- 239000000427 antigen Substances 0.000 claims abstract description 27
- 108091007433 antigens Proteins 0.000 claims abstract description 27
- 102000036639 antigens Human genes 0.000 claims abstract description 27
- 238000003018 immunoassay Methods 0.000 claims abstract description 25
- 101710169678 Histidine-rich protein Proteins 0.000 claims abstract description 7
- 102100034612 Annexin A4 Human genes 0.000 claims abstract description 6
- 238000003556 assay Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 230000002163 immunogen Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 238000002965 ELISA Methods 0.000 claims description 15
- 239000000020 Nitrocellulose Substances 0.000 claims description 15
- 208000009182 Parasitemia Diseases 0.000 claims description 15
- 208000030852 Parasitic disease Diseases 0.000 claims description 15
- 239000002250 absorbent Substances 0.000 claims description 15
- 230000002745 absorbent Effects 0.000 claims description 15
- 229920001220 nitrocellulos Polymers 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 12
- 230000003053 immunization Effects 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 11
- 239000002502 liposome Substances 0.000 claims description 11
- 210000004408 hybridoma Anatomy 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000013641 positive control Substances 0.000 claims description 5
- 239000003365 glass fiber Substances 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 13
- 230000008878 coupling Effects 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 12
- 239000002245 particle Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 201000004792 malaria Diseases 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 108010076441 Ala-His-His Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100033620 Calponin-1 Human genes 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 3
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 230000002788 anti-peptide Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000012229 microporous material Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- WAAXYLYXYLKHJZ-UHFFFAOYSA-N 1-[3-(1-hydroxy-2,5-dioxopyrrolidine-3-carbonyl)phenyl]pyrrole-2,5-dione Chemical compound O=C1N(O)C(=O)CC1C(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 WAAXYLYXYLKHJZ-UHFFFAOYSA-N 0.000 description 2
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 2
- ATAKEVCGTRZKLI-UWJYBYFXSA-N Ala-His-His Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ATAKEVCGTRZKLI-UWJYBYFXSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KWBISLAEQZUYIC-UWJYBYFXSA-N His-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CN=CN2)N KWBISLAEQZUYIC-UWJYBYFXSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 210000000973 gametocyte Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002764 solid phase assay Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- -1 sulfo SMCC Chemical compound 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- WKALLSVICJPZTM-UHFFFAOYSA-N 3-[decyl(dimethyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O WKALLSVICJPZTM-UHFFFAOYSA-N 0.000 description 1
- USWINTIHFQKJTR-UHFFFAOYSA-N 3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=CC2=C1 USWINTIHFQKJTR-UHFFFAOYSA-N 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- DKJPOZOEBONHFS-ZLUOBGJFSA-N Ala-Ala-Asp Chemical group C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O DKJPOZOEBONHFS-ZLUOBGJFSA-N 0.000 description 1
- JDIQCVUDDFENPU-ZKWXMUAHSA-N Ala-His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CNC=N1 JDIQCVUDDFENPU-ZKWXMUAHSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- CVLIHKBUPSFRQP-WHFBIAKZSA-N Cys-Gly-Ala Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C)C(O)=O CVLIHKBUPSFRQP-WHFBIAKZSA-N 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical group SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- UKPBEPCQTDRZSE-UHFFFAOYSA-N cyclizine hydrochloride Chemical compound Cl.C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UKPBEPCQTDRZSE-UHFFFAOYSA-N 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 108010044853 histidine-rich proteins Proteins 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- NAHBVNMACPIHAH-HLICZWCASA-N p-ii Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC2=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)=O)C(C)C)C1=CC=CC=C1 NAHBVNMACPIHAH-HLICZWCASA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000006226 wash reagent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94528792A | 1992-09-11 | 1992-09-11 | |
| US07/945,287 | 1992-09-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2104899A1 CA2104899A1 (en) | 1994-03-12 |
| CA2104899C true CA2104899C (en) | 2000-10-17 |
Family
ID=25482919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002104899A Expired - Fee Related CA2104899C (en) | 1992-09-11 | 1993-08-26 | Antibodies to plasmodium falciparum |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US5478741A (OSRAM) |
| EP (1) | EP0588122B1 (OSRAM) |
| JP (1) | JP2537589B2 (OSRAM) |
| AU (2) | AU670108B2 (OSRAM) |
| CA (1) | CA2104899C (OSRAM) |
| DE (1) | DE69321914T2 (OSRAM) |
| ES (1) | ES2124276T3 (OSRAM) |
| MY (1) | MY109957A (OSRAM) |
| SG (1) | SG48314A1 (OSRAM) |
| TW (1) | TW258738B (OSRAM) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9403819D0 (en) * | 1994-02-28 | 1994-04-20 | Univ Leeds | Control of parasites |
| GB9505447D0 (en) * | 1995-03-17 | 1995-05-03 | Common Services Agency | Competitive binding assay |
| US20030036106A1 (en) * | 1996-10-28 | 2003-02-20 | Burke Thomas J. | Kinase and phosphatase activity measurement using fluorescence polarization |
| WO1998051794A1 (en) * | 1997-05-14 | 1998-11-19 | Human Genome Sciences, Inc. | Antimicrobial peptide |
| US20020102620A1 (en) * | 1999-05-07 | 2002-08-01 | S. Melissa Maret | Antibodies and peptides for detection of plasmodium vivax |
| WO2000079283A1 (en) | 1999-06-23 | 2000-12-28 | Cornell Research Foundation, Inc. | Dehydration/rehydration of marked liposomes on a test device |
| US6576460B1 (en) | 1999-10-28 | 2003-06-10 | Cornell Research Foundation, Inc. | Filtration-detection device and method of use |
| WO2003102541A2 (en) | 2002-05-31 | 2003-12-11 | Cornell Research Foundation, Inc. | Universal biosensor and methods of use |
| AU2003270619A1 (en) | 2002-09-12 | 2004-04-30 | Molecular Probes, Inc. | Site-specific labeling of affinity tags in fusion proteins |
| FR2865541B1 (fr) * | 2003-05-20 | 2006-08-11 | Commissariat Energie Atomique | Procede de detection de fluorure ou de fluorure d'hydrogene et trousse de detection |
| EP1718967B1 (en) * | 2004-02-03 | 2013-04-24 | Diadexus, Inc. | METHODS OF DETECTING Lp-PLA2 ACTIVITY |
| KR101035111B1 (ko) * | 2004-06-30 | 2011-05-19 | 주식회사 엘지생명과학 | 말라리아 플라스모듐 팔시파룸의 면역학적 측정방법 및이에 사용되는 측정 수단 |
| JP4508765B2 (ja) * | 2004-08-02 | 2010-07-21 | 東洋紡績株式会社 | ペプチドの固定化方法 |
| JP4599928B2 (ja) * | 2004-08-02 | 2010-12-15 | 東洋紡績株式会社 | ペプチドの固定化方法 |
| WO2006081308A2 (en) * | 2005-01-25 | 2006-08-03 | The Johns Hopkins University | Plasmodium diagnostic assay device |
| ES2353212T3 (es) * | 2005-03-30 | 2011-02-28 | Saladax Biomedical Inc. | Inmunoensayo de doxorrubicina. |
| US20070072242A1 (en) * | 2005-09-22 | 2007-03-29 | Randox Laboratories Limited | Immunoassay method and kit to leucomalachite green and malachite green |
| EP1991273B2 (en) * | 2006-02-10 | 2022-01-05 | Life Technologies Corporation | Labeling and detection of post translationally modified proteins |
| CA2653408C (en) * | 2006-05-27 | 2017-08-01 | Mitchell A. Winnik | Polymer backbone element tags |
| WO2008008797A2 (en) | 2006-07-10 | 2008-01-17 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| PT2047270E (pt) * | 2006-07-28 | 2013-10-17 | Beckman Coulter Inc | Agentes de estabilização e ligandos de captura para utilização em ensaios de medição de concentrações de analito |
| WO2008100344A2 (en) | 2006-10-06 | 2008-08-21 | Sirigen Inc. | Fluorescent methods and materials for directed biomarker signal amplification |
| TWI368905B (en) | 2006-11-17 | 2012-07-21 | Princeton Technology Corp | Circuits for generating radio frequency zero cross signal of optical disc drive |
| US9239329B2 (en) * | 2006-12-18 | 2016-01-19 | Japan Science And Technology Agency | Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods |
| FR2914066B1 (fr) * | 2007-03-20 | 2009-05-22 | Polyintell Sarl | Kit d'analyse comprenant au moins deux polymeres a empreintes moleculaires et au moins un marqueur, ainsi que le procede d'analyse l'utilisant |
| US8320230B2 (en) | 2007-05-17 | 2012-11-27 | Mediatek Inc. | Processing circuits and methods for optical data |
| US7943370B2 (en) * | 2007-08-23 | 2011-05-17 | Canon Kabushiki Kaisha | Structure, target substance detection element and target substance detection kit |
| WO2009097159A1 (en) * | 2008-02-02 | 2009-08-06 | Tropical Health Systems Llc | A blood purification method and appartus for the treatment of malaria |
| WO2010051544A2 (en) * | 2008-10-31 | 2010-05-06 | Lumiphore, Inc. | Rapid homogeneous diagnostic testing platform based on lanthanide fluorescent resonance energy transfer |
| EP2816038B8 (en) | 2009-08-24 | 2019-12-25 | Lumiphore, Inc. | Hopo chelators |
| EP3263562A1 (en) * | 2009-12-24 | 2018-01-03 | Lumiphore, Inc. | Radiopharmaceutical complexes |
| WO2011119609A1 (en) * | 2010-03-23 | 2011-09-29 | Board Of Trustees Of Michigan State University | Histidine rich protein-2 diagnostic test for cerebral malaria |
| EP2611827A4 (en) * | 2010-09-03 | 2014-03-19 | Univ Oregon Health & Science | RECOMBINANT T-CELL RECEPTOR LIGANDS WITH Covalently Bonded PEPTIDES |
| US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
| EP3077815B1 (en) * | 2013-12-03 | 2019-07-17 | President and Fellows of Harvard College | Methods and reagents for the assessment of gestational diabetes |
| GB201409516D0 (en) * | 2014-05-29 | 2014-07-16 | Randox Lab Ltd | Immunoassay for compounds of the NBOMe family |
| EP3265074B1 (en) * | 2015-03-03 | 2020-08-12 | ARK Diagnostics, Inc. | Pregabalin immunoassays |
| EP3288912A4 (en) * | 2015-05-01 | 2018-11-07 | Biolegend, Inc. | Stable nanomagnetic particle dispersions |
| KR102705120B1 (ko) * | 2016-02-26 | 2024-09-09 | 어질런트 테크놀러지스, 인코포레이티드 | 친핵체의 표지화를 개선시키기 위한 비스피리딘의 용도 |
| EP3440463B1 (en) * | 2016-04-05 | 2020-07-08 | Université de Strasbourg | Intra-droplet surface engineering to capture a molecular target |
| WO2017190117A1 (en) | 2016-04-30 | 2017-11-02 | BioLegend, Inc. | Compositions and methods for performing magnetibuoyant separations |
| JP7303182B2 (ja) | 2017-04-21 | 2023-07-04 | メリタス エルエルシー | 糖尿病関連用途のための方法及び抗体 |
| CN120801474A (zh) * | 2018-04-13 | 2025-10-17 | 富鲁达加拿大公司 | 用于元素分析的稳定细胞采集 |
| CN111378034B (zh) * | 2018-12-29 | 2021-10-12 | 东莞市朋志生物科技有限公司 | 抗恶性疟原虫hrp-ii抗体 |
| CN111378035B (zh) * | 2018-12-29 | 2021-10-08 | 东莞市朋志生物科技有限公司 | 抗恶性疟原虫hrp-ii重组抗体 |
| CN114605533B (zh) * | 2020-12-08 | 2023-02-28 | 东莞市朋志生物科技有限公司 | 抗恶性疟原虫hrp-ii的抗体、检测恶性疟原虫的试剂和试剂盒 |
| US20220214350A1 (en) * | 2021-01-05 | 2022-07-07 | Encodia, Inc. | Methods for stable complex formation and related kits |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE388694B (sv) | 1975-01-27 | 1976-10-11 | Kabi Ab | Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4666866A (en) | 1983-04-19 | 1987-05-19 | Krauth Gary H | Immunoassay for antigens employing supported binder |
| US4493795A (en) * | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US4703017C1 (en) | 1984-02-14 | 2001-12-04 | Becton Dickinson Co | Solid phase assay with visual readout |
| US4695554A (en) | 1984-02-14 | 1987-09-22 | Becton Dickinson And Company | Sac or liposome containing dye (sulforhodamine) for immunoassay |
| US4743560A (en) | 1984-03-26 | 1988-05-10 | Becton Dickinson And Company | Solid phase assay |
| US4632901A (en) | 1984-05-11 | 1986-12-30 | Hybritech Incorporated | Method and apparatus for immunoassays |
| GB2169901A (en) | 1984-12-11 | 1986-07-23 | Lkb Biochrom Ltd | method for a solid phase synthesis of a linear combination of amino acid residues. |
| WO1986006075A1 (en) * | 1985-04-11 | 1986-10-23 | The Walter And Eliza Hall Institute Of Medical Res | Highly repetitive antigens of plasmodium falciparum |
| AU5603786A (en) * | 1985-04-11 | 1986-10-16 | Walter And Eliza Hall Institute Of Medical Research, The | Highly repetitive antigens - sharp-arp-mesa-plasmodium falciparum |
| US5130416A (en) * | 1986-08-13 | 1992-07-14 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA clone containing a genomic fragment of PfHRP-II gene from plasmodium falciparum |
| US5030558A (en) | 1986-11-07 | 1991-07-09 | Syntex (U.S.A.) Inc. | Qualitative immunochromatographic method and device |
| US5001225A (en) * | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
| US4920046A (en) | 1987-02-20 | 1990-04-24 | Becton, Dickinson And Company | Process, test device, and test kit for a rapid assay having a visible readout |
| US4855240A (en) | 1987-05-13 | 1989-08-08 | Becton Dickinson And Company | Solid phase assay employing capillary flow |
| AU2384688A (en) * | 1987-09-04 | 1989-03-31 | Georgetown University | Monoclonal antibodies to a plasmodium falciparum protein |
| DE3737238A1 (de) * | 1987-11-03 | 1989-05-18 | Behringwerke Ag | Rekombinantes histidinreiches protein (37 kd antigen) von plasmodium falciparum, seine herstellung und verwendung |
| US4818677A (en) | 1987-12-03 | 1989-04-04 | Monoclonal Antibodies, Inc. | Membrane assay using focused sample application |
| US5096837A (en) | 1990-02-08 | 1992-03-17 | Pacific Biotech, Inc. | Immunochromatographic assay and method of using same |
| EP0474891A1 (en) * | 1990-09-08 | 1992-03-18 | BEHRINGWERKE Aktiengesellschaft | Vectors for expression of malarial antigens on the surface of Salmonella vaccine strains |
| JP2002054521A (ja) | 2000-08-11 | 2002-02-20 | Honda Motor Co Ltd | エンジンの燃料ポンプ取付構造 |
-
1993
- 1993-08-24 AU AU44872/93A patent/AU670108B2/en not_active Ceased
- 1993-08-26 CA CA002104899A patent/CA2104899C/en not_active Expired - Fee Related
- 1993-08-27 EP EP93113737A patent/EP0588122B1/en not_active Expired - Lifetime
- 1993-08-27 DE DE69321914T patent/DE69321914T2/de not_active Expired - Fee Related
- 1993-08-27 SG SG1996008855A patent/SG48314A1/en unknown
- 1993-08-27 ES ES93113737T patent/ES2124276T3/es not_active Expired - Lifetime
- 1993-09-10 MY MYPI93001845A patent/MY109957A/en unknown
- 1993-09-13 JP JP5227486A patent/JP2537589B2/ja not_active Expired - Fee Related
- 1993-10-27 TW TW082108967A patent/TW258738B/zh active
-
1994
- 1994-05-27 US US08/250,309 patent/US5478741A/en not_active Expired - Lifetime
-
1995
- 1995-03-21 US US08/408,418 patent/US5665552A/en not_active Expired - Fee Related
- 1995-03-21 US US08/408,092 patent/US5604117A/en not_active Expired - Lifetime
-
1996
- 1996-09-06 AU AU64499/96A patent/AU683000B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69321914T2 (de) | 1999-03-25 |
| EP0588122A1 (en) | 1994-03-23 |
| JPH06225789A (ja) | 1994-08-16 |
| AU6449996A (en) | 1996-12-12 |
| ES2124276T3 (es) | 1999-02-01 |
| US5478741A (en) | 1995-12-26 |
| AU683000B2 (en) | 1997-10-23 |
| MY109957A (en) | 1997-10-31 |
| JP2537589B2 (ja) | 1996-09-25 |
| CA2104899A1 (en) | 1994-03-12 |
| US5604117A (en) | 1997-02-18 |
| EP0588122B1 (en) | 1998-11-04 |
| AU670108B2 (en) | 1996-07-04 |
| DE69321914D1 (de) | 1998-12-10 |
| SG48314A1 (en) | 1998-04-17 |
| TW258738B (OSRAM) | 1995-10-01 |
| US5665552A (en) | 1997-09-09 |
| AU4487293A (en) | 1994-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2104899C (en) | Antibodies to plasmodium falciparum | |
| US5874527A (en) | Plasmodium vivax blood stage antigens | |
| US4935343A (en) | Monoclonal antibodies for interleukin-1β | |
| CA2406240C (en) | Hcv anti-core monoclonal antibodies | |
| US7670805B2 (en) | Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 | |
| WO1994028413A9 (en) | Plasmodium vivax blood stage antigens, antibodies, and diagnostic assays | |
| Nascimento et al. | Immunodiagnosis of human cysticercosis (Taenia solium) with antigens purified by monoclonal antibodies | |
| Fujii et al. | Localization of biologically uncommon D-beta-aspartate-containing alphaA-crystallin in human eye lens | |
| US20020102620A1 (en) | Antibodies and peptides for detection of plasmodium vivax | |
| JP3978226B2 (ja) | アルコール中毒患者を同定しアルコール消費を監視するためのイムノアッセイ | |
| CN102229913A (zh) | 一种用于检测疟原虫的胶体金快速免疫层析检测试纸及抗体和细胞株 | |
| Chao et al. | Characterization of monoclonal and polyclonal antibodies to human tissue kallikrein. | |
| Ruangjirachuporn et al. | Monoclonal antibodies to a synthetic peptide corresponding to a repeated sequence in the Plasmodium falciparum antigen Pf155 | |
| JP5492366B2 (ja) | 炭水化物欠失トランスフェリン（ｃｄｔ）特異的抗体、その製造および使用 | |
| CA2036237A1 (en) | Immunoassay methods using noncross reactive cea gene family member antibodies | |
| US6133427A (en) | Anti-human calcitonin monoclonal antibodies and an immunoassay utilizing said antibodies | |
| KR100493932B1 (ko) | 레지스틴에 대한 단클론 항체, 이의 제조 방법, 및 용도 | |
| JPH0284175A (ja) | 人フィブリノペプチドａに特異な単クローン性抗体 | |
| US5646247A (en) | Merozoite antigens localized at the apical end of the parasite | |
| Ahlborg et al. | Generation of antibodies to human IL-12 and amphiregulin by immunization of Balb/c mice with diepitope multiple antigen peptides | |
| US20110243950A1 (en) | Msp2 antigenic peptides and their use | |
| WO2003074555A2 (en) | Synthetic peptides from c. difficile | |
| Mercereau‐Puijalon et al. | Cross‐reaction of antibodies to the nine‐amino acid repeats of Plasmodium falciparum antigen 11.1 with human serum albumin | |
| CA2525499A1 (en) | Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |